表紙:嚢胞性線維症治療の世界市場 (2021-2027年):市場予測 (治療法・流通経路別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア
市場調査レポート
商品コード
1027228

嚢胞性線維症治療の世界市場 (2021-2027年):市場予測 (治療法・流通経路別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア

Cystic Fibrosis Therapeutics Market Size By Treatment Method, By Distribution Channel, COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 100 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
嚢胞性線維症治療の世界市場 (2021-2027年):市場予測 (治療法・流通経路別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア
出版日: 2021年09月06日
発行: Global Market Insights Inc.
ページ情報: 英文 100 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

嚢胞性線維症治療の市場は新しい治療の発見と開発への世界的な注力から、2027年にかけて大幅な成長を示すと予測されています。

治療法別で見ると、2020年に9%のシェアを示した治療器具の部門が予測期間中も安定的成長を示すと予測されています。また、流通経路別では、小売薬局の部門が2020年に35%のシェアを示し、予測期間中も堅調な成長が見込まれています。先進諸国では小売薬局の普及が進んでおり、今後数年は同部門の普及が進むと予測されています。

当レポートでは、世界の嚢胞性線維症治療の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、治療法・流通経路・地域/主要国など各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 産業考察

  • 産業の分類
  • 産業情勢
  • 産業への影響要因
    • 成長要因
    • 潜在的リスク&課題
  • 成長の可能性
  • COVID-19:影響分析
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 市場分析・予測:治療法別

  • 投薬
  • 治療器具
  • その他

第5章 市場分析・予測:流通経路別

  • 病院
  • 小売薬局
  • その他

第6章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • ラテンアメリカ
  • その他の地域

第7章 企業プロファイル

  • 戦略ダッシュボード
  • Vertex Pharmaceuticals Incorporated
  • Roche
  • Nestle Health Science
  • Abbvie
  • Viatris Inc
  • Horizon Therapeutics plc
  • Gilead
  • Chiesi Farmaceutici
  • Pharmaxis Ltd
  • Teva Pharmaceuticals
図表

Data Tables

  • TABLE 1 Cystic fibrosis therapeutics industry 360 degree synopsis, 2016 - 2027
  • TABLE 2 Cystic fibrosis therapeutics market, 2016-2027 (USD Million)
  • TABLE 3 Cystic fibrosis therapeutics market, by treatment method, 2016-2027 (USD Million)
  • TABLE 4 Cystic fibrosis medications market, by drug class, 2016-2027 (USD Million)
  • TABLE 5 Cystic fibrosis medications market, by route of administration, 2016-2027 (USD Million)
  • TABLE 6 Cystic fibrosis therapeutics market, by distribution channel, 2016-2027 (USD Million)
  • TABLE 7 Cystic fibrosis therapeutics market, by region, 2016-2027 (USD Million)
  • TABLE 8 Industry impact forces
  • TABLE 9 Medications market size, by region, 2016-2027 (USD Million)
  • TABLE 10 CFTR modulators market size, by region, 2016-2027 (USD Million)
  • TABLE 11 Mucolytics market size, by region, 2016-2027 (USD Million)
  • TABLE 12 Bronchodilators market size, by region, 2016-2027 (USD Million)
  • TABLE 13 Pancreatic enzyme supplements market size, by region, 2016-2027 (USD Million)
  • TABLE 14 Others market size, by region, 2016-2027 (USD Million)
  • TABLE 15 Oral Drugs market size, by region, 2016-2027 (USD Million)
  • TABLE 16 Inhaled Drugs market size, by region, 2016-2027 (USD Million)
  • TABLE 17 Devices market size, by region, 2016-2027 (USD Million)
  • TABLE 18 Others market size, by region, 2016-2027 (USD Million)
  • TABLE 19 Hospitals market size, by region, 2016-2027 (USD Million)
  • TABLE 20 Retail pharmacies market size, by region, 2016-2027 (USD Million)
  • TABLE 21 Other market size, by region, 2016-2027 (USD Million)
  • TABLE 22 North America cystic fibrosis therapeutics market size, by country, 2016-2027 (USD Million)
  • TABLE 23 North America cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 24 North America cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 25 North America cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 26 North America cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 27 U.S. Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 28 U.S. cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 29 U.S. cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 30 U.S. Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 31 Canada Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 32 Canada cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 33 Canada cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 34 Canada Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 35 Europe Cystic fibrosis therapeutics market size, by country, 2016-2027 (USD Million)
  • TABLE 36 Europe Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 37 Europe cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 38 Europe cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 39 Europe Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 40 Germany Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 41 Germany cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 42 Germany cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 43 Germany Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 44 France Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 45 France cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 46 France cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 47 France Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 48 UK Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 49 UK cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 50 UK cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 51 UK Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 52 Italy Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 53 Italy cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 54 Italy cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 55 Italy cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 56 Spain cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 57 Spain cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 58 Spain cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 59 Spain cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 60 Latin America Cystic fibrosis therapeutics market size, by country, 2016-2027 (USD Million)
  • TABLE 61 Latin America Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 62 Latin America cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 63 Latin America cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 64 Latin America Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 65 Brazil Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 66 Brazil cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 67 Brazil cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 68 Brazil Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 69 Mexico Cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 70 Mexico cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 71 Mexico cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 72 Mexico Cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 73 RoW cystic fibrosis therapeutics market size, by country, 2016-2027 (USD Million)
  • TABLE 74 RoW cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 75 RoW cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 76 RoW cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 77 RoW cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 78 Australia cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 79 Australia cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 80 Australia cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 81 Australia cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)
  • TABLE 82 South Africa cystic fibrosis therapeutics market size, by treatment method, 2016-2027 (USD Million)
  • TABLE 83 South Africa cystic fibrosis medications market size, by drug class, 2016-2027 (USD Million)
  • TABLE 84 South Africa cystic fibrosis medications market size, by route of administration, 2016-2027 (USD Million)
  • TABLE 85 South Africa cystic fibrosis therapeutics market size, by distribution channel, 2016-2027 (USD Million)

Charts & Figures

  • FIG. 1 Industry segmentation
  • FIG. 2 Global cystic fibrosis therapeutics market size, 2016 - 2027 (USD Million)
  • FIG. 3 Growth potential analysis, by treatment method
  • FIG. 4 Growth potential analysis, by distribution channel
  • FIG. 5 Porter's analysis
  • FIG. 6 Competitive matrix analysis, 2020
  • FIG. 7 PESTEL analysis
  • FIG. 8 Key segment trends, by treatment method
  • FIG. 9 Key segment trends, by distribution channel
  • FIG. 10 Key regional trends, by region
  • FIG. 11 Strategy dashboard, 2020
目次
Product Code: 5118

The cystic fibrosis therapeutics market is projected to observe substantial growth by 2027 owing to surging focus on the discovery and development of novel treatment therapies around the world.

Cystic fibrosis (CF) is a genetic condition that makes patients susceptible to recurrent and chronic lung infections. In patients suffering from cystic fibrosis, the CFTR protein becomes dysfunctional as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This condition causes glands to produce mucus and sweat that is sticky and thick, thereby clogging airways and damaging organs.

The ongoing COVID-19 outbreak has necessitated the development of innovative therapies for the treatment of various types of lung infections and diseases. As a result, multiple scientific investigations undertaken by medical laboratories have facilitated market expansion in key regions across the globe.

Notably, prominent industry participants are employing lucrative business tactics to monetize favorable market trends by introducing new products, building strategic partnerships, and acquisitions, which have enhanced overall market dynamics. For instance, in March 2021, Pharmaxis Ltd., an Australian pharmaceutical company, announced that its cystic fibrosis treatment, Bronchitol, had been launched in the U.S. by Chiesi USA, Ltd., a leading pharmaceutical firm. Pharmaxis received a total payment of USD 10 million for the stock of Bronchitol that is being commercialized in the United States by Chiesi.

In another instance, in July 2021, biopharmaceutical giant AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc., a global biopharmaceutical company. Through the acquisition, AstraZeneca improved scientific discoveries and developed suitable medications for people with rare diseases using Alexion's strong pipeline and innovative complement-biology platform.

The cystic fibrosis therapeutics market has been segmented on the basis of distribution channel, treatment method, and region. In terms of treatment method, the market has further been categorized into devices, medications, and others.

The devices sub-segment held a market share of around 9% in 2020 and is expected to grow at a steady pace over 2021-2027. Soaring demand for devices used to cure cystic fibrosis is likely to drive segmental growth in the forthcoming years.

With respect to distribution channel, the cystic fibrosis therapeutics market has been bifurcated into retail pharmacies, hospitals, and others. In 2020, the retail pharmacies sub-segment accounted for nearly 35% market share and is slated to observe optimistic growth over the forecast timeline. Mounting prevalence of retail pharmacies in developed economies is slated to bolster segmental adoption over the following years.

From the regional point of view, the North America cystic fibrosis therapeutics market attained a valuation of more than USD 6 billion in 2020 and is estimated to amass considerable gains by the end of 2027. Growing number of CF patients in the region is set to drive market expansion through the review period.

Table of Contents

Chapter 1 Methodology

  • 1.1 Methodology
  • 1.2 Market definitions
  • 1.3 Forecast parameters
  • 1.4 Data sources
    • 1.4.1 Secondary
      • 1.4.1.1 Paid sources
      • 1.4.1.2 Unpaid sources
    • 1.4.2 Primary

Chapter 2 Executive Summary

  • 2.1 Cystic fibrosis therapeutics industry 360 degree synopsis, 2016 - 2027
    • 2.1.1 Business trends
    • 2.1.2 Treatment method trends
    • 2.1.3 Distribution channel trends
    • 2.1.4 Regional trends

Chapter 3 Cystic Fibrosis Therapeutics Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Rise in incidence of cystic fibrosis
      • 3.3.1.2 Advancements in therapeutics for treatment of cystic fibrosis in developed regions
      • 3.3.1.3 Rising awareness and adoption of treatment procedures developing regions
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Low awareness in developing nations
      • 3.3.2.2 High cost of surgical treatment
  • 3.4 Growth potential analysis
    • 3.4.1 By treatment method
    • 3.4.2 By distribution channel
  • 3.5 COVID-19 impact analysis
  • 3.6 Porter's analysis
  • 3.7 Competitive landscape, 2020
    • 3.7.1 Competitive matrix analysis, 2020
  • 3.8 PESTEL analysis

Chapter 4 Cystic Fibrosis Therapeutics Market, By Treatment Method

  • 4.1 Key segment trends
  • 4.2 Medications
    • 4.2.1 Market size, by region, 2016 - 2027
    • 4.2.2 Market size, by Drug class, 2016 - 2027
      • 4.2.2.1 CFTR modulators
        • 4.2.2.1.1 Market size, by region, 2016 - 2027
      • 4.2.2.2 Mucolytics
        • 4.2.2.2.1 Market size, by region, 2016 - 2027
      • 4.2.2.3 Bronchodilators
        • 4.2.2.3.1 Market size, by region, 2016 - 2027
      • 4.2.2.4 Pancreatic enzyme supplements
        • 4.2.2.4.1 Market size, by region, 2016 - 2027
      • 4.2.2.5 Others
        • 4.2.2.5.1 Market size, by region, 2016 - 2027
    • 4.2.3 Market Size, by route of administration, 2016 - 2027
      • 4.2.3.1 Oral drugs
        • 4.2.3.1.1 Market size, by region, 2016 - 2027
      • 4.2.3.2 Inhaled drugs
        • 4.2.3.2.1 Market size, by region, 2016 - 2027
  • 4.3 Devices
    • 4.3.1 Market size, by region, 2016 - 2027
  • 4.4 Others
    • 4.4.1 Market size, by region, 2016 - 2027

Chapter 5 Cystic Fibrosis Therapeutics Market, By Distribution Channel

  • 5.1 Key segment trends
  • 5.2 Hospitals
    • 5.2.1 Market size, by region, 2016 - 2027
  • 5.3 Retail pharmacies
    • 5.3.1 Market size, by region, 2016 - 2027
  • 5.4 Others
    • 5.4.1 Market size, by region, 2016 - 2027

Chapter 6 Cystic Fibrosis Therapeutics Market, By Region

  • 6.1 Key regional trends
  • 6.2 North America
    • 6.2.1 Market size, by country, 2016 - 2027
    • 6.2.2 Market size, by treatment method, 2016 - 2027
      • 6.2.2.1 Medications market size, by drug class, 2016 - 2027
      • 6.2.2.2 Medications market size, by route of administration, 2016 - 2027
    • 6.2.3 Market size, by distribution channel, 2016 - 2027
    • 6.2.4 U.S.
      • 6.2.4.1 Market size, by treatment method, 2016 - 2027
        • 6.2.4.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.2.4.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.2.4.2 Market size, by distribution channel, 2016 - 2027
    • 6.2.5 Canada
      • 6.2.5.1 Market size, by treatment method, 2016 - 2027
        • 6.2.5.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.2.5.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.2.5.2 Market size, by distribution channel, 2016 - 2027
  • 6.3 Europe
    • 6.3.1 Market size, by country, 2016 - 2027
    • 6.3.2 Market size, by treatment method, 2016 - 2027
      • 6.3.2.1 Medications market size, by drug class, 2016 - 2027
      • 6.3.2.2 Medications market size, by route of administration, 2016 - 2027
    • 6.3.3 Market size, by distribution channel, 2016 - 2027
    • 6.3.4 Germany
      • 6.3.4.1 Market size, by treatment method, 2016 - 2027
        • 6.3.4.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.3.4.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.3.4.2 Market size, by distribution channel, 2016 - 2027
    • 6.3.5 France
      • 6.3.5.1 Market size, by treatment method, 2016 - 2027
        • 6.3.5.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.3.5.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.3.5.2 Market size, by distribution channel, 2016 - 2027
    • 6.3.6 UK
      • 6.3.6.1 Market size, by treatment method, 2016 - 2027
        • 6.3.6.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.3.6.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.3.6.2 Market size, by distribution channel, 2016 - 2027
    • 6.3.7 Italy
      • 6.3.7.1 Market size, by treatment method, 2016 - 2027
        • 6.3.7.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.3.7.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.3.7.2 Market size, by distribution channel, 2016 - 2027
    • 6.3.8 Spain
      • 6.3.8.1 Market size, by treatment method, 2016 - 2027
        • 6.3.8.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.3.8.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.3.8.2 Market size, by distribution channel, 2016 - 2027
  • 6.4 Latin America
    • 6.4.1 Market size, by country, 2016 - 2027
    • 6.4.2 Market size, by treatment method, 2016 - 2027
      • 6.4.2.1 Medications market size, by drug class, 2016 - 2027
      • 6.4.2.2 Medications market size, by route of administration, 2016 - 2027
    • 6.4.3 Market size, by distribution channel, 2016 - 2027
    • 6.4.4 Brazil
      • 6.4.4.1 Market size, by treatment method, 2016 - 2027
        • 6.4.4.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.4.4.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.4.4.2 Market size, by distribution channel, 2016 - 2027
    • 6.4.5 Mexico
      • 6.4.5.1 Market size, by treatment method, 2016 - 2027
        • 6.4.5.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.4.5.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.4.5.2 Market size, by distribution channel, 2016 - 2027
  • 6.5 Rest of the world
    • 6.5.1 Market size, by country, 2016 - 2027
    • 6.5.2 Market size, by treatment method, 2016 - 2027
      • 6.5.2.1 Medications market size, by drug class, 2016 - 2027
      • 6.5.2.2 Medications market size, by route of administration, 2016 - 2027
    • 6.5.3 Market size, by distribution channel, 2016 - 2027
    • 6.5.4 Australia
      • 6.5.4.1 Market size, by treatment method, 2016 - 2027
        • 6.5.4.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.5.4.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.5.4.2 Market size, by distribution channel, 2016 - 2027
    • 6.5.5 South Africa
      • 6.5.5.1 Market size, by treatment method, 2016 - 2027
        • 6.5.5.1.1 Medications market size, by drug class, 2016 - 2027
        • 6.5.5.1.2 Medications market size, by route of administration, 2016 - 2027
      • 6.5.5.2 Market size, by distribution channel, 2016 - 2027

Chapter 7 Company Profiles

  • 7.1 Strategy dashboard, 2020
  • 7.2 Vertex Pharmaceuticals Incorporated
    • 7.2.1 Business overview
    • 7.2.2 Financial data
    • 7.2.3 Product landscape
    • 7.2.4 Strategic outlook
    • 7.2.5 SWOT analysis
  • 7.3 Roche
    • 7.3.1 Business overview
    • 7.3.2 Financial data
    • 7.3.3 Product landscape
    • 7.3.4 Strategic outlook
    • 7.3.5 SWOT analysis
  • 7.4 Nestle Health Science
    • 7.4.1 Business overview
    • 7.4.2 Financial data
    • 7.4.3 Product landscape
    • 7.4.4 Strategic outlook
    • 7.4.5 SWOT analysis
  • 7.5 Abbvie
    • 7.5.1 Business overview
    • 7.5.2 Financial data
    • 7.5.3 Product landscape
    • 7.5.4 Strategic outlook
    • 7.5.5 SWOT analysis
  • 7.6 Viatris Inc
    • 7.6.1 Business overview
    • 7.6.2 Financial data
    • 7.6.3 Product landscape
    • 7.6.4 Strategic outlook
    • 7.6.5 SWOT analysis
  • 7.7 Horizon Therapeutics plc
    • 7.7.1 Business overview
    • 7.7.2 Financial data
    • 7.7.3 Product landscape
    • 7.7.4 Strategic outlook
    • 7.7.5 SWOT analysis
  • 7.8 Gilead
    • 7.8.1 Business overview
    • 7.8.2 Financial data
    • 7.8.3 Product landscape
    • 7.8.4 Strategic outlook
    • 7.8.5 SWOT analysis
  • 7.9 Chiesi Farmaceutici
    • 7.9.1 Business overview
    • 7.9.2 Financial data
    • 7.9.3 Product landscape
    • 7.9.4 Strategic outlook
    • 7.9.5 SWOT analysis
  • 7.10 Pharmaxis Ltd
    • 7.10.1 Business overview
    • 7.10.2 Financial data
    • 7.10.3 Product landscape
    • 7.10.4 Strategic outlook
    • 7.10.5 SWOT analysis
  • 7.11 Teva Pharmaceuticals
    • 7.11.1 Business overview
    • 7.11.2 Financial data
    • 7.11.3 Product landscape
    • 7.11.4 Strategic outlook
    • 7.11.5 SWOT analysis